Clobetasol propionate is a super-high potency topical corticosteroid of the glucocorticoid class. It is one of the most potent topical steroids available, exerting potent anti-inflammatory, antipruritic, and vasoconstrictive actions. It is primarily used for short-term treatment of severe, resistant inflammatory and pruritic dermatoses. In the Indian context, it is widely prescribed but requires careful monitoring due to its high potency and significant risk of local and systemic adverse effects, especially with prolonged use or on large body surface areas.
Adult: Apply a thin film to the affected area once or twice daily. Maximum duration: 2-4 weeks. Maximum weekly dose should not exceed 50 grams (or 50 ml of lotion/shampoo).
Note: Wash and dry the area gently. Apply a thin layer and rub in lightly. Do not apply under occlusive dressings unless specifically directed by a physician for a severe, localized condition. Wash hands after application unless hands are the treatment site. Avoid contact with eyes, mouth, and mucous membranes.
Clobetasol propionate is a synthetic glucocorticoid that binds with high affinity to cytoplasmic glucocorticoid receptors. The drug-receptor complex translocates to the cell nucleus, where it modulates gene transcription. It induces the synthesis of anti-inflammatory proteins (lipocortin-1) and inhibits the synthesis of pro-inflammatory mediators.
Pregnancy: Pregnancy Category C (US FDA). Animal studies show teratogenicity. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus, especially in the first trimester. Avoid large doses, prolonged use, or application to large areas.
Driving: No known effects on driving ability.
| Other Topical Corticosteroids | Increased risk of additive local and systemic side effects, including HPA axis suppression. | Major |
| Systemic Corticosteroids (e.g., Prednisolone) | Additive systemic effects, significantly increased risk of HPA axis suppression and Cushingoid features. | Major |
| Immunosuppressants (e.g., Tacrolimus, Pimecrolimus - topical) | Theoretical increased risk of immunosuppression and infection; concurrent use not generally recommended. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | May inhibit the metabolism of systemically absorbed clobetasol, potentially increasing systemic exposure and toxicity. | Moderate |
Same composition (Clobetasol (NA)), different brands: